Honokiol inhibits hypoxia-inducible factor-1 pathway

References

• Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. 2003. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumour growth in vivo. Journal of Biological Chemistry 278:35501–35507.
   PubMed Web of Science ®Google Scholar
• Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Hsien Lee Y, Lin S. 2003. GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochemical and Biophysical Research Communications 302:95–100.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, Hu X. 2004. Honokiol: A potent chemotherapy candidate for human colorectal carcinoma. World Journal of Gastroenterology 10: 3459–3463.
   PubMed Web of Science ®Google Scholar
• Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE. 1999. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. Journal of Biological Chemistry 274:33709–33713.
   PubMed Web of Science ®Google Scholar
• Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. 2009. Honokiol-mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. Journal of Immunotherapy 32:585–592.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Cao Y, Moeller B. 2008. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer 8:425–437.
   PubMed Web of Science ®Google Scholar
• Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. 1999. Noninvasive assessment of tumour cell proliferation in animal models. Neoplasia 1:303–310.
   PubMedGoogle Scholar
• Fu B, Xue J, Li Z, Shi X, Jiang BH, Fang J. 2007. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Molecular Cancer Therapy 6:220–226.
   PubMed Web of Science ®Google Scholar
• Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 277:38205–38211.
   PubMed Web of Science ®Google Scholar
• Giaccia A, Siim BG, Johnson RS. 2003. HIF-1 as a target for drug development. Nature Reviews Drug Discovery 2:803–811.
   PubMed Web of Science ®Google Scholar
• Hahm ER, Arlotti JA, Marynowski SW, Singh SV. 2008. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clinical Cancer Research 14:1248–1257.
   PubMed Web of Science ®Google Scholar
• Hibasami H, Achiwa Y, Katsuzaki H, Imai K, Yoshioka K, Nakanishi K, Ishii Y, Hasegawa M, Komiya T. 1998. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. International Journal of Molecular Medicine 2:671–673.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth and Differentiation 12:363–369.
   PubMedGoogle Scholar
• Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G. 2005. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Research 65:9047–9055.
   PubMed Web of Science ®Google Scholar
• Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. 2010. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumour effects of epidermal growth factor receptor inhibitors. Clinical Cancer Research 16:2571–2579.
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. 2004. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10:594–601.
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Cao Y, Li CY, Dewhirst MW. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumours: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441.
   PubMed Web of Science ®Google Scholar
• Nagase H, Ikeda K, Sakai Y. 2001. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Medica 67:705–708.
   PubMed Web of Science ®Google Scholar
• Neckers L. 2002. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends in Molecular Medicine 8:S55–61.
   PubMed Web of Science ®Google Scholar
• Palfreyman MG. 2002. Human tissue in target identification and drug discovery. Drug Discovery Today 7:407–409.
   PubMed Web of Science ®Google Scholar
• Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK. 2009. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Letters 277:133–140.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Giaccia AJ. 2008. The role of hypoxia-inducible factors in tumourigenesis. Cell Death and Differentiation 15:678–685.
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. 2004. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Research 64:1475–1482.
   PubMed Web of Science ®Google Scholar
• Rho JK, Choi YJ, Lee JK, Ryoo BY, Na, II, Yang SH, Kim CH, Yoo YD, Lee JC. 2009. Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha. Oncology Reports 21:801–807.
   PubMed Web of Science ®Google Scholar
• Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3(10):721–732.
   PubMed Web of Science ®Google Scholar
• Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625–634.
   PubMed Web of Science ®Google Scholar
• Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW. 2007. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109:1279–1289.
   PubMed Web of Science ®Google Scholar
• Shinohara ET, Maity A. 2009. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumour microenvironment. Current Molecular Medicine 9:1034–1045.
   PubMed Web of Science ®Google Scholar
• Sodhi A, Montaner S, Miyazaki H, Gutkind JS. 2001. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochemical and Biophysical Research Communications 287:292–300.
   PubMed Web of Science ®Google Scholar
• Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH. 1999. Visualizing the kinetics of tumour-cell clearance in living animals. Proceedings of the National Academy of Sciences of the USA 96:12044–12049.
   PubMed Web of Science ®Google Scholar
• Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson, JJ, Pereira MM, Nicolaou KC, Van Meir EG. 2005. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Research 65:605–612.
   PubMed Web of Science ®Google Scholar
• Tsai TH, Chou CJ, Cheng FC, Chen CF. 1994. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 655:41–45.
   PubMed Web of Science ®Google Scholar
• Tse AK, Wan CK, Shen XL, Yang M, Fong WF. 2005. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochemical Pharmacology 70:1443–1457.
   PubMed Web of Science ®Google Scholar
• Wang T, Chen F, Chen Z, Wu YF, Xu XL, Zheng S, Hu X. 2004. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World Journal of Gastroenterology 10:2205–2208.
   PubMed Web of Science ®Google Scholar
• Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP. 2007. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. International Journal of Oncology 30:1529–1537.
   PubMed Web of Science ®Google Scholar
• Won MS, Im N, Park S, Boovanahalli SK, Jin Y, Jin X, Chung KS, Kang M, Lee K, Park SK and others. 2009. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochemical and Biophysical Research Communications 385:16–21.
   PubMed Web of Science ®Google Scholar
• Xu D, Lu Q, Hu X. 2006. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Letters 243:274–280.
   PubMed Web of Science ®Google Scholar
• Yang SE, Hsieh MT, Tsai TH, Hsu SL. 2002. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochemical Pharmacology 63:1641–1651.
   PubMed Web of Science ®Google Scholar
• Zhong H, Willard M, Simons J. 2004. NS398 reduces hypoxia-inducible factor (HIF)- 1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer 112: 585–595.
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumour angiogenesis and therapeutics. Cancer Research 60:1541–1545.
   PubMed Web of Science ®Google Scholar
• Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 14:391–396.
   PubMed Web of Science ®Google Scholar